Almirall SAS has announced that full results from two pivotal Phase III clinical trials assessing the efficacy and safety of once-daily dosing of linaclotide 290 mcg in patients with IBS-C shows that linaclotide significantly improved abdominal pain/discomfort and relieved IBS-C symptoms. The impact of linaclotide on patients' quality of life from baseline to 12 weeks was measured using the Irritable Bowel Syndrome - Quality of Life Questionnaire (IBS-QoL). Pooled data from the two Phase III trials show that linaclotide statistically significantly improved IBS-QoL overall scores and seven out of eight important QoL domains (dysphoria, body image, health worry, sexual relationships, food avoidance and social reaction) compared with placebo in adults with IBS-C (p<0.001). The data also demonstrate that the proportion of patients meeting responder criteria for a 10-point or 14-point change from baseline was statistically significantly greater for patients treated with linaclotide versus placebo at week 12 for the IBS-QoL overall and all eight subscale scores (p<0.05).

Almirall SAS has appointed Daniel Carretero as its CFO, effective July 1, 2011. Daniel will also be heading the areas of Purchasing, Information Systems (IT) and Investor Relations. He joined Almirall in September 2008 as Deputy CFO reporting to Eduardo Sanchiz, then Director of Corporate Development and Finance. During this period Daniel Martínez has led the finance area jointly with Eduardo Sanchiz and has been responsible for various organizational and finance projects as well as being a member of the Management Board. Prior to joining Almirall he spent several years in PepsiCo in a variety of roles in the finance area, finally holding the position of Finance Director Iberia. After PepsiCo, Daniel continued his career in Reckitt Benckiser as Finance Director for South East Europe.